Cardiovascular safety of indacaterol, a novel 24-hour β2 -agonist, in patients with stable asthma
A. Chuchalin, A. Tsoi, K. Richter, R. Cameron, W. Bao, A. van As (Moscow, Russian Federation; Grosshansdorf, Germany; Horsham, United Kingdom; East Hanover, United States Of America)
Source: Annual Congress 2005 - Novel therapies for asthma
Session: Novel therapies for asthma
Session type: Poster Discussion
Number: 1728
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Chuchalin, A. Tsoi, K. Richter, R. Cameron, W. Bao, A. van As (Moscow, Russian Federation; Grosshansdorf, Germany; Horsham, United Kingdom; East Hanover, United States Of America). Cardiovascular safety of indacaterol, a novel 24-hour β2 -agonist, in patients with stable asthma. Eur Respir J 2005; 26: Suppl. 49, 1728
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Safety of multiple-dose indacaterol, a novel 24-hour β2 -agonist, in moderate to severe COPD Source: Eur Respir J 2005; 26: Suppl. 49, 295s Year: 2005
Safety and tolerability of multiple-dose indacaterol, a novel 24-hour β2 -agonist, in patients with mild asthma Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005
Cardiovascular safety of qva149, a novel combination of indacaterol and glycopyrronium, compared with indacaterol and placebo in patients with COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009
Cardiac safety of indacaterol, a novel once-daily bronchodilator, in asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Cardiovascular safety of salmeterol in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 240s Year: 2002
Cardiovascular safety of long-term therapy with combination bronchodilator in patients with stable COPD Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004
Cardiac safety of indacaterol, a novel once-daily bronchodilator, in COPD Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
Single-dose indacaterol, a novel 24-hour β2 -agonist, is well tolerated in patients with mild asthma Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005
24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma, and comparison with formoterol Source: Annual Congress 2008 - New treatments for asthma Year: 2008
24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015
Safety and effectiveness of indacaterol in Korean COPD patients: A post-marketing surveillance (PMS) study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
Overall and cardiovascular safety of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in patients with COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
NVA237 once daily provides rapid, clinically meaningful and sustained 24-h bronchodilation in patients with COPD: The GLOW1 trial Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006
Indacaterol, a novel once-daily β2 -agonist, provides effective 24-hour bronchodilation in moderate-to-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006
24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD, and comparison with formoterol Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation vs placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009
Comparison of cardiovascular safety in a pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014
Indacaterol, a novel β2 -agonist, demonstrates 24-hour efficacy and is well tolerated in patients with asthma: a multiple-dose, dose-ranging study Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005